scholarly journals Hodgkin’s Disease in Childhood

Blood ◽  
1973 ◽  
Vol 42 (2) ◽  
pp. 163-174 ◽  
Author(s):  
Robert C. Young ◽  
Vincent T. DeVita ◽  
Ralph E. Johnson
Keyword(s):  
Combination Chemotherapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Single Agent ◽  
Stage Iv ◽  
Entire Group ◽  
The Past ◽  
Initial Stage ◽  
Localized Disease ◽  
Single Agent Chemotherapy

Abstract Thirty-eight children with Hodgkin’s disease have been treated over the past 8 yr with either intensive radiotherapy or combination chemotherapy (MOPP), depending on their initial stage. The median survival of the entire group of children has not yet been reached, as 63% are still alive, but it will be in excess of 58 mo. Median survivals by stage are as follows: stage I, greater than 46 mo; stage II, greater than 46 mo; stage III, 35 mo; and stage IV, 26.7 mo. Although the numbers of children are small, these results appear significantly superior to published reports utilizing less intensive radiotherapy and single-agent chemotherapy and suggest that intensive radiotherapy for localized disease and combination chemotherapy for advanced disease may, at present, be the preferred forms of therapy for Hodgkin’s disease in childhood.

scholarly journals Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin’s Disease

Blood ◽  
1970 ◽  
Vol 36 (6) ◽  
pp. 704-717 ◽  
Author(s):  
STANLEY LOWENBRAUN ◽  
VINCENT T. DEVITA ◽  
ARTHUR A. SERPICK
Keyword(s):  
Combination Chemotherapy ◽  
Hodgkin's Disease ◽  
Nitrogen Mustard ◽  
Hodgkin’S Disease ◽  
Stage Iv ◽  
Stage Iv Disease ◽  
Radiotherapy Alone ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
Systemic Symptoms

Abstract Combination chemotherapy with four drugs—nitrogen mustard, vincristine, procarbazine and prednisone—was used in 27 previously treated patients with advanced progressive Hodgkin’s disease. Six 2-week cycles of chemotherapy were administered in the following schedule: nitrogen mustard, 6 mg./sq.M. I.V., and vincristine, 1.4 mg./sq.M. I.V., on days 1 and 8 of each cycle; procarbazine, 100 mg./sq.M. by mouth daily throughout each cycle, and prednisone, 40 mg./sq.M. orally each day of cycles 1 and 4. Each cycle was followed by a 2-week period during which no drug was given. Twenty-two patients had Stage IV disease and 17 had systemic symptoms at the time of drug administration. All patients had histories of previous therapy. Two received chemotherapy alone, 15 had radiotherapy alone and 10 had both chemotherapy and radiotherapy. Nineteen out of the 27 patients (70%) had complete responses (total regression of all lesions) to the four drug combination and five patients (19%) had partial responses (50% regression of all lesions). Fourteen out of the 19 who responded completely are still in unmaintained remission 1-24 months from therapy completion. Eighteen out of the 19 who responded completely are still surviving from 6 to 30 months after the start of combination chemotherapy. Those patients treated previously with both radiotherapy and chemotherapy did not respond as well as patients treated with prior radiotherapy alone. In general, therapy was well tolerated, with leukopenia being the major dosage-limiting toxicity. There was a progressively poorer tolerance to the drugs with increasing extent of prior radiotherapy.

scholarly journals Primary Nongestational Choriocarcinoma of the Ovary

2014 ◽  
Vol 4 (1) ◽  
pp. 56-59
Author(s):  
AMM Shariful Alam ◽  
Syeda Nurjahan Bhuiyan ◽  
Md Rashid Un Nabi
Keyword(s):  
Germ Cell ◽  
Combination Chemotherapy ◽  
Single Agent ◽  
Ovarian Pregnancy ◽  
Cell Neoplasm ◽  
Aggressive Tumor ◽  
Single Agent Chemotherapy ◽  
Disease Free ◽  
Worse Prognosis ◽  
Unmarried Girl

Pure primary ovarian choriocarcinoma is an extremely rare and aggressive tumor. It can be of gestational or nongestational in origin. The gestational type can arise from an ovarian pregnancy or can be of metastatic origin from uterine choriocarcinoma. The nongestational type is a very rare germ cell neoplasm. It is important to distinguish between two types of choriocarcinomas as nongestational origin is highly malignant and has worse prognosis than gestational type. But it is very difficult to differentiate by routine histological examination. Nongestational choriocarcinoma has been found to be resistant to single agent chemotherapy. It occurs usually around 13 years of age and is mainly confined to females under 20. Here we report a case of primary pure nongestational choriocarcinoma of the ovary in an unmarried girl of 14 years, diagnosed in 2001 and treated successfully with surgery and combination chemotherapy and remained disease-free till last reporting in September 2013. DOI: http://dx.doi.org/10.3329/jemc.v4i1.18070 J Enam Med Col 2014; 4(1): 56-59

scholarly journals Bordetella bronchiseptica infection in stage IV Hodgkin's disease

1981 ◽  
Vol 57 (673) ◽  
pp. 723-724 ◽  
Author(s):  
D. B. Stoll ◽  
S. A. Murphey ◽  
S. K. Ballas
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Stage Iv ◽  
Bordetella Bronchiseptica

Combination Chemotherapy of Advanced Hodgkin’s Disease with Adriamycin, DTIC, CCNU, and Bleomycin

Chemotherapy ◽  
1976 ◽  
pp. 513-516
Author(s):  
R. Osieka ◽  
U. Bruntsch ◽  
W. M. Gallmeier ◽  
S. Seeber ◽  
C. G. Schmidt
Keyword(s):  
Combination Chemotherapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Advanced Hodgkin’S Disease
Sign in / Sign up

Export Citation Format

Share Document